The in-house engineering activities transfer products from research to production and develop new processes in the GPM environment. In the future, lean processes and the modular infrastructure will enable rapid capacity expansion by means of scale-ups.
The scale-up projects are used to investigate which formulation and product adaptations are necessary in order to produce the products in larger quantities. The expansion of the Nanofactory will not only ensure the production of the quantities required for the clinical trials, but also secure the volumes for future market entry.
Important process steps from production and quality control through to filling are now automated. For example, InnoMedica's own filling robots were developed in collaboration with universities and industry partners to fill clinically usable vials. This approach was chosen because outsourcing is very expensive, and the expertise generated in the process is ultimately not anchored within the company itself. With this much more cost-effective solution, which is precisely tailored to the needs of the company, InnoMedica is again going its own path in order to invest as cost-effectively as possible and build up the expertise in-house.
